Academic Journal
Lipid-lowering with inclisiran: areal-world single-centre experience
| العنوان: | Lipid-lowering with inclisiran: areal-world single-centre experience |
|---|---|
| المؤلفون: | Padam, P, Barton, L, Wilson, S, David, A, Walji, S, De Lorenzo, F, Ray, K, Jones, B, Cegla, J |
| بيانات النشر: | BMJ Publishing Group |
| سنة النشر: | 2022 |
| المجموعة: | Imperial College London: Spiral |
| الوصف: | Objective The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction. Inclisiran is a new and potent lipid-lowering drug that is shown to be effective in reducing LDL-c in randomised controlled trials, however, real-world data of its use are not yet known. We sought to analyse the early effects of this drug in a tertiary centre lipid and cardiovascular risk clinic. Methods We performed a retrospective analysis of the first 80 patients who received a single dose of inclisiran at our lipid clinic between 1 December 2021 and 1 September 2022. Data were collected using electronic healthcare records. Baseline blood tests were taken prior to start of treatment and were repeated at 2 months follow-up. Data on adverse events were also recorded. Results At 2 months after treatment initiation, mean baseline LDL-c fell from 3.5±1.1 mmol/L by 48.6% to 1.8±1.0 mmol/L and total cholesterol from 5.7±1.3 mmol/L by 33.3% to 3.8±1.1 mmol/L (both p<0.0001). Mean high-density lipoprotein-c rose by 7.7% to 1.4±0.4 mmol/L (p=0.02) and median triglycerides fell by 31.3% to 1.1 mmol/L (IQR 0.9–2) (p=0.001). Adverse events (injection site reaction, fatigue and headache) were recorded in three patients and all had self-resolved by time of follow-up. Conclusion Inclisiran use in line with National Institute for Health and Care Excellence guidelines led to significant lowering of LDL-c at 2 months, with efficacy similar to that reported in trials with good tolerability. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 2053-3624 |
| Relation: | Open Heart; http://hdl.handle.net/10044/1/101963 |
| DOI: | 10.1136/openhrt-2022-002184 |
| الاتاحة: | http://hdl.handle.net/10044/1/101963 https://doi.org/10.1136/openhrt-2022-002184 |
| Rights: | © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. ; http://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.FEC6E21D |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20533624 |
|---|---|
| DOI: | 10.1136/openhrt-2022-002184 |